Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Entera Bio Ltd. WT EXP 062723 ENTXW NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
28/100
1/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Entera Bio Ltd. WT EXP 062723 (ENTXW) is a Biotechnology company in the Healthcare sector, currently trading at $0.00. It has a SharesGrow Score of 26/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Financials: revenue is $42,000, -88.4%/yr average growth. Net income is $11M (loss), growing at +1.6%/yr. Net profit margin is -27235.7% (negative). Gross margin is -71.4% (-96 pp trend).

Balance sheet: total debt is $490,000 against $13M equity (Debt-to-Equity (D/E) ratio 0.04, conservative). Current ratio is 3.23 (strong liquidity). Debt-to-assets is 3.1%. Total assets: $16M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 30/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 0/100 (Fail), Future ?/100 (Fail), Income 10/100 (Fail).

ENTXW SharesGrow Score Overview

47/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 30/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 0/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ENTXW

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
30/100
ENTXW: -88.4%/yr revenue is, +1.6%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet ENTXW: Debt-to-Equity (D/E) ratio 0.04 (conservative), Current ratio is 3.23 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
—
MOAT N/A
N/A
No analyst coverage available for this stock.
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
✗
INCOME Fail
10/100
ENTXW: Net profit margin is -27235.7%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.001-0.003
Volume26.48K
Beta (1Y)0.00
Share Statistics
EPS (TTM)-0.25
Shares Outstanding$46.19M
IPO Date2018-06-28
CEONone
Financial Highlights & Ratios
Revenue (TTM)$42K
Gross Profit$-30K
EBITDA$-11.5M
Net Income$-11.44M
Operating Income$-11.53M
Total Cash$7.11M
Total Debt$490K
Net Debt$-6.62M
Total Assets$15.99M
Price / Earnings (P/E)-0
Analyst Forecast
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD

Price Chart

Track all markets on TradingView
ENTXW
Entera Bio Ltd. WT EXP 062723  ·  NASDAQ Capital Marke
Healthcare • Biotechnology
0.00 52WK RANGE 0.00

People Also View

IMACW
IMACW
IMAC Holdings, Inc.
$0.01
+10.09%
 ARTLW
ARTLW
Artelo Biosciences, Inc.
$0.01
+0.00%
 ADILW
ADILW
Adial Pharmaceuticals, Inc. WT EXP 073123
$0.00
-57.14%
 CREXW
CREXW
Creative Realities, Inc. WT EXP 110922
$0.00
+6.98%
 MDGSW
MDGSW
Medigus Ltd. WT C EXP 072323
$0.02
-7.79%
 LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message